Haleon (LSE:HLN) is the world’s largest pure-play consumer health Business, home to global brands including Sensodyne, parodontax, Panadol, Voltaren, Advil, Centrum, Theraflu and Otrivin. Spun out of GSK in 2022, the FTSE 100 group has spent the past three years building its own identity as a standalone listed company. In 2025, Pfizer completed its full exit from Haleon, leaving the business with a fully independent Shareholder register. After delivering organic Revenue growth of 3.0% in FY 2025 and continuing a multi-year buyback programme, Haleon remains firmly on the radar for UK investors looking for defensive growth.

This article reviews Haleon’s recent results, share price, Dividend record and the trends shaping the company. It is a journalist’s overview of publicly available information and is not Investment advice.

Key takeaways

  • Haleon delivered FY 2025 organic revenue growth of 3.0%, comprising 2.3% price and 0.7% Volume/mix, according to its full-year results.
  • Oral Health organic revenue grew 7.9% in FY 2025, led by Sensodyne and parodontax.
  • FY 2025 adjusted operating profit Margin was 24.5%, up 50 basis points on an organic basis.
  • Pfizer completed its exit from Haleon on 21 March 2025, selling a 7.3% stake for around £2.55 billion ($3.3 billion).
  • Haleon planned around £500 million of share Buybacks in 2025, including approximately £170 million repurchased directly from Pfizer.
  • In May 2026, Haleon’s US-listed shares were quoted at around $9.01, with a Market Capitalisation of about $40 billion.

Why investors are watching this FTSE 100 stock

Haleon is unique in the FTSE 100 as a focused, large-cap consumer health business. Unlike Reckitt Benckiser, which combines consumer health with hygiene and infant nutrition, and Unilever, which spans food, personal care and home care, Haleon is dedicated to OTC health, oral health, pain relief, vitamins, minerals and supplements (VMS), respiratory health and digestive health. That focus is attractive for investors who want defensive growth without diluted exposure.

UK investors are also watching Haleon because of its global Brand portfolio. According to the company, Sensodyne, parodontax, Panadol, Voltaren, Advil, Centrum, Theraflu and Otrivin are leaders in their respective categories. Long-term drivers include ageing populations in developed markets, expanding middle classes in emerging markets and the broader shift from prescription to OTC for many minor health conditions.

The completion of Pfizer’s exit in March 2025, after GSK had previously sold down its position, has also been important. With both founding pharmaceutical parents now fully separated from Haleon, the business has a cleaner ownership structure and improved free float, which can support inclusion in additional indices and broader institutional ownership.

Recent share price performance

Where the shares sit in May 2026

Haleon’s US-listed shares were quoted at around $9.01 in May 2026, with a day’s trading range of $8.98-$9.09 reported. The company’s market capitalisation was approximately $40 billion, putting Haleon firmly among the larger FTSE 100 consumer staples names.

Drivers of the 2026 move

The share price has reflected a mix of factors: steady, if modest, organic growth; margin expansion; the completion of the Pfizer exit; and the ongoing buyback programme. Investors have also weighed broader debates about consumer staples valuations and the impact of weight-management drugs on parts of the wellness sector.

Longer-term context

Since its 2022 demerger from GSK, Haleon has navigated a period of significant strategic and ownership change. Both GSK and Pfizer have sold their stakes, with Pfizer’s final exit in March 2025 completing a series of four transactions through which it raised approximately $13.4 billion (£10.3 billion) in total. The company has used Capital returns, including share buybacks, to support shareholder returns through the transition.

Business performance and Earnings

Haleon’s FY 2025 organic revenue growth of 3.0% comprised 2.3% from price and 0.7% from volume/mix. The standout category was Oral Health, which grew 7.9% on an organic basis, driven by Sensodyne and parodontax. Pain relief organic growth was 3.7% in Q3 2025, led by Panadol, helped by continued rollout of Panadol Dual Action.

Performance was uneven across categories. VMS declined low-single digit on an organic basis, with a decline in Centrum that improved in H2. Respiratory Health declined mid-single digit, with a double-digit decline in Q4 from a weaker cold and flu season. Overall, the company’s adjusted operating profit margin was 24.5% in FY 2025, up 50 basis points on an organic basis, according to the full-year results.

Looking forward, Haleon’s strategy continues to emphasise category innovation, Market Share gains and expansion in emerging markets. Investors are watching how the company manages the more cyclical respiratory and VMS categories alongside the structurally faster-growing oral health portfolio.

Dividends and shareholder returns

Haleon has built a track record of dividend payments since its demerger. Reported dividend data is denominated in different currencies depending on source. According to US-listed share data, Haleon has an annual dividend of $0.31 per ADR with a Yield of around 3.10%, while other sources cite a yield of around 2.1% for the London-listed shares. The dividend is paid every six months, with the last ex-dividend date in April 2026 and the next payment estimated for June 2026.

Alongside the dividend, share buybacks have been a meaningful part of Haleon’s capital return story. According to the company, the shares repurchased from Pfizer in March 2025 formed part of a planned £500 million share buyback programme for 2025, with approximately £170 million repurchased directly from Pfizer. Buybacks have continued to be a feature of the company’s capital allocation framework.

UK investors should consider that dividend payments are subject to changes in earnings, free Cash Flow and management’s capital allocation choices. Buybacks, while attractive when shares trade below Intrinsic Value, also depend on the discipline with which they are executed.

Valuation and market position

Haleon trades as a focused global consumer health company, sitting in a peer group that includes Kenvue, Reckitt Benckiser (which combines consumer health with hygiene and infant nutrition), Bayer Consumer Health, Sanofi Consumer Health and Procter & Gamble’s personal health businesses. Within the FTSE 100, Haleon is a distinctive pure-play, offering UK investors a way to access the global OTC theme through a London-listed share.

Valuation multiples for Haleon reflect its mid-single-digit organic growth profile, defensive characteristics, strong cash generation and emerging market exposure. Market commentary often debates whether the shares deserve a premium to the broader consumer staples sector given the structural attractions of consumer health, or whether near-term softness in respiratory and VMS categories limits the upside. According to company commentary, margin expansion and disciplined capital allocation are central pillars of the investment story.

A key valuation Factor for global investors is the dual UK listing and US ADR programme. The completion of Pfizer’s exit and increased free float can support broader index inclusion and institutional investment flows, which over time may influence multiples and trading Liquidity.

Sector trends shaping Haleon

Demand for consumer health products is supported by several structural trends. Ageing populations in developed markets, expanding middle classes in emerging markets, the gradual shift from prescription to over-the-counter products and increased consumer engagement with everyday health and wellness all play a role. Haleon’s portfolio sits squarely within these themes.

Within categories, oral health has been a particularly strong performer, with Sensodyne and parodontax delivering 7.9% organic revenue growth in FY 2025. Pain relief is also benefitting from product innovation, including Panadol Dual Action. By contrast, VMS has faced category-level pressures, especially in Centrum, and respiratory health is sensitive to the strength of each year’s cold and flu season.

Currency, regulation and consumer trade-down behaviour are constant variables. According to company commentary, Haleon is investing in brand-building, science-based claims and emerging market distribution to support medium-term growth. Newer trends such as the rise of GLP-1 weight-management drugs are also being assessed for their impact on parts of the wellness and digestive health space.

Risks to watch

Category cyclicality is one of Haleon’s most discussed risks. Respiratory Health revenues are heavily influenced by the severity of the cold and flu season, and the FY 2025 results showed a mid-single-digit decline in this category with a double-digit fall in Q4. VMS has also experienced periods of weakness, particularly in Centrum. Together, these mean that quarter-to-quarter performance can be more volatile than the broad consumer staples reputation might suggest.

Litigation risk has been another recurring topic. Haleon has been involved in commentary around historical heartburn medication litigation in the US, although a number of legal developments have been reported across the wider industry. Investors should monitor disclosures and judgements as the legal landscape evolves.

Other risks include competition from peers and private label, currency translation effects on global earnings, regulatory changes in major markets, Supply chain disruption and the broader trajectory of consumer spending. According to the company, ongoing investment in brand, innovation and emerging markets is aimed at mitigating these risks, but outcomes remain uncertain.